Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
30 04 2020
Historique:
received: 26 08 2019
accepted: 01 03 2020
pubmed: 18 3 2020
medline: 22 12 2020
entrez: 18 3 2020
Statut: ppublish

Résumé

Clonal hematopoiesis (CH) is associated with age and an increased risk of myeloid malignancies, cardiovascular risk, and all-cause mortality. We tested for CH in a setting where hematopoietic stem cells (HSCs) of the same individual are exposed to different degrees of proliferative stress and environments, ie, in long-term survivors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and their respective related donors (n = 42 donor-recipient pairs). With a median follow-up time since allo-HSCT of 16 years (range, 10-32 years), we found a total of 35 mutations in 23 out of 84 (27.4%) study participants. Ten out of 42 donors (23.8%) and 13 out of 42 recipients (31%) had CH. CH was associated with older donor and recipient age. We identified 5 cases of donor-engrafted CH, with 1 case progressing into myelodysplastic syndrome in both donor and recipient. Four out of 5 cases showed increased clone size in recipients compared with donors. We further characterized the hematopoietic system in individuals with CH as follows: (1) CH was consistently present in myeloid cells but varied in penetrance in B and T cells; (2) colony-forming units (CFUs) revealed clonal evolution or multiple independent clones in individuals with multiple CH mutations; and (3) telomere shortening determined in granulocytes suggested ∼20 years of added proliferative history of HSCs in recipients compared with their donors, with telomere length in CH vs non-CH CFUs showing varying patterns. This study provides insight into the long-term behavior of the same human HSCs and respective CH development under different proliferative conditions.

Identifiants

pubmed: 32181816
pii: S0006-4971(20)62063-8
doi: 10.1182/blood.2019003079
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1548-1559

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© 2020 by The American Society of Hematology.

Auteurs

Steffen Boettcher (S)

Department of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

C Matthias Wilk (CM)

Department of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.

Jochen Singer (J)

Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
SIB Swiss Institute of Bioinformatics, Basel, Switzerland.

Fabian Beier (F)

Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.

Elodie Burcklen (E)

Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.

Christian Beisel (C)

Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.

Monica S Ventura Ferreira (MS)

Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.

Elise Gourri (E)

Blood Transfusion Service Zurich, Zurich, Switzerland; and.

Christoph Gassner (C)

Blood Transfusion Service Zurich, Zurich, Switzerland; and.

Beat M Frey (BM)

Blood Transfusion Service Zurich, Zurich, Switzerland; and.

Urs Schanz (U)

Department of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.

Radek C Skoda (RC)

Department of Biomedicine, Experimental Hematology, University Hospital Basel and University of Basel, Basel, Switzerland.

Benjamin L Ebert (BL)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

Tim H Brummendorf (TH)

Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.

Niko Beerenwinkel (N)

Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
SIB Swiss Institute of Bioinformatics, Basel, Switzerland.

Markus G Manz (MG)

Department of Medical Oncology and Hematology, University of Zurich and University Hospital Zurich, Zurich, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH